This inventor holds 2 USPTO granted patents. Top assignees: Luxembourg Institute of Science and Technology, Universitè Catholique De Louvain, Université Libre De Bruxelles. Active years: 2015-2026.
Company Filing History:
1 out of 75 
1 out of 100 
1 out of 99 
Years Active: 2015-2026
Title: Joelle Leclercq: Innovator in Anti-Cancer Research
Introduction
Joelle Leclercq is a prominent inventor based in Beaufays, Belgium. She has made significant contributions to the field of anti-cancer research, particularly through her innovative work on phenazine derivatives. Her research focuses on developing compounds that can serve as effective anti-angiogenic and anti-tumor agents.
Latest Patents
Joelle Leclercq holds a patent for "Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents." This patent describes novel phenazine derivatives that can be utilized in the treatment of cancer. The compounds disclosed in her patent have the potential to inhibit tumor growth and angiogenesis, making them valuable in cancer therapy. She has 1 patent to her name.
Career Highlights
Throughout her career, Joelle has worked with esteemed institutions such as Université Catholique de Louvain and Université Libre de Bruxelles. Her research has garnered attention for its innovative approach to cancer treatment, and she continues to be a leading figure in her field.
Collaborations
Joelle has collaborated with notable researchers, including Olivier Feron and Olivier Riant. These partnerships have furthered her research and contributed to advancements in anti-cancer therapies.
Conclusion
Joelle Leclercq is a trailblazer in the field of anti-cancer research, with her innovative patents paving the way for new treatment options. Her dedication to developing effective anti-angiogenic and anti-tumor agents highlights her significant impact on medical science.